Blood-Based Alzheimer's Diagnostics Advance with Multiple New Tests and Commercialization Deals

Alamar launched multiplexed eMTBR-Tau test. ALZpath-Abbott and Alzinova-Fujirebio partnerships push pTau217 toward commercialization. A new circRNA-based blood test predicts symptom onset 2-4 years ahead, outperforming pTau217 by 29 points in prognostic AUC; combined model achieved AUC 0.98, commercially launched. CARDIA study links blood biomarkers to midlife cognitive decline. Consumer at-home testing emerging but equity and false positive concerns remain. AAIC conference upcoming. Real-world data: PrecivityAD2 in primary care showed accuracy jump from 62% to 88%, changed care plans for 62% of patients. A longitudinal study on blood-based biomarker changes adds further evidence. A study provides concrete risk estimates for p-tau217 in asymptomatic individuals: 38% over 5 years, 78% over 10 years for very high levels, but notes no preventive treatments yet. Recent articles clarify that FDA-approved tests are currently only for symptomatic adults 55+ with cognitive decline, not for asymptomatic screening. A new AAIC study provides the clearest risk estimates yet: 24% and 38% over 5 years for high and very high p-tau217 levels in asymptomatic adults. Alamar gained commercial rights to develop clinical IVD tests using ALZpath's antibody. New: Validation of Lumipulse G p-tau217 and PrecivityAD2 in adults with Down syndrome, a high-risk population, with established thresholds for amyloid detection.